FDA Person
Center for Drug Evaluation and ResearchKassa Ayalew
View detailed information about Kassa Ayalew, including compliance records, violations, and related data.
Person Profile
FDA investigator, Center for Drug Evaluation and Research. Took part in 5 inspections of 5 companies, 2017–2019.
Inspections (5)
| Date | Company | Classification | Project area | Inspection |
|---|---|---|---|---|
| September 6, 2019 | Cyrille Hulin, M.D. | NAI | Bioresearch Monitoring | #1105936 |
| August 15, 2019 | PPD, Inc., part of Thermo Fisher Scientific | VAI | Bioresearch Monitoring | #1099603 |
| December 14, 2018 | Novartis Pharmaceuticals Corporation | VAI | Bioresearch Monitoring | #1074476 |
| January 12, 2018 | Conrado Estol, M.D. | VAI | Bioresearch Monitoring | #1044217 |
| July 19, 2017 | Chemo Research S.L.U. | NAI | Bioresearch Monitoring | #1023824 |
Documents (3)
- WARNING LETTER · Doft, Bernard H. M.D. · September 28, 2012
- EIR · GlaxoSmithKline LLC · April 10, 2015
- 483 · PPD, Inc., part of Thermo Fisher Scientific · August 15, 2019
Frequently inspected with (6)
Related Office
Person Information
Name
Kassa Ayalew
Role
Regulatory Personnel
ID: e16b339e-6db4-4c0e-91ae-b70d586d9d97
Get More Insights
Access our comprehensive quality intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.
1.5M+ regulatory data points
Real-time compliance monitoring
Interactive analytics dashboard
Looking for more people? Our platform provides access to thousands of FDA people with advanced search and filtering capabilities.
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust KeyPedia for their regulatory compliance needs.